Related Experiment Video
Updated: Oct 18, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
Effectiveness of a Problem-Solving Program in Improving Problem-Solving Ability and Glycemic Control for Diabetics
Fei-Ling Wu1,2, Chia-Hung Lin2,3, Chia-Ling Lin1
1Department of Nursing, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan.
International Journal of Environmental Research and Public Health
|September 28, 2021
Summary
The hypoglycemia problem-solving program (HPSP) improved glycemic control and problem-solving skills in diabetic patients with hypoglycemia. This intervention led to better HbA1c levels and enhanced hypoglycemia problem-solving ability.
Area of Science:
- Endocrinology
- Diabetes Management
- Health Education
Background:
- Hypoglycemia is a common complication in diabetes management.
- Effective problem-solving skills are crucial for patients to manage hypoglycemia.
- Existing interventions may not adequately address the problem-solving aspect of hypoglycemia.
Purpose of the Study:
- To evaluate the impact of a hypoglycemia problem-solving program (HPSP) on problem-solving ability.
- To assess the effect of HPSP on glycemic control (HbA1c) in diabetic patients experiencing hypoglycemia.
Main Methods:
- Prospective, quasi-experimental study with pre- and post-repeated measures design.
- 71 diabetic patients with hypoglycemia were assigned to an experimental (HPSP, n=34) or control (usual care, n=37) group.
- Assessments of HbA1c and hypoglycemia problem-solving scale (HPSS) were conducted at baseline, 1, 3, and 6 months post-intervention.
Main Results:
- The experimental group showed significant improvement in HbA1c levels 6 months post-HPSP intervention compared to baseline.
- Hypoglycemia problem-solving scale (HPSS) scores improved significantly at all follow-up points in the HPSP group.
- While the control group showed minor HPSS score improvements, the HPSP group demonstrated superior outcomes in both HbA1c and HPSS scores over time.
Conclusions:
- The hypoglycemia problem-solving program (HPSP) is an effective intervention for improving glycemic control in diabetic patients with hypoglycemia.
- HPSP significantly enhances patients' ability to problem-solve hypoglycemia-related issues.
- The findings support the integration of structured problem-solving programs into diabetes care for better patient outcomes.
Related Concept Videos
01:15Hypoglycemia and Glucagon
461
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
461
01:15Diabetes: Management and Pharmacotherapy
570
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
570
01:23Dipeptidyl Peptidase 4 Inhibitors
293
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
293
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
320
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
320
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
346
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
346
01:06Oral Hypoglycemic Agents: Glinides
308
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
308